Severe eczema in Wiskott–Aldrich syndrome‐related disorder successfully treated with dupilumab
Fatmah Alzahrani, Holly Miller, Keith Sacco, Elizabeth Dupuy
Abstract
Treatment of severe eczema in patients with primary immunodeficiencies can be particularly challenging as there are no guidelines with regards to these conditions. Dupilumab is an interleukin (IL)-4Rα antagonist that inhibits both IL-4 and IL-13 and is approved for the treatment of atopic dermatitis in pediatric patients. In this report, we describe a patient with a case of severe eczema in the context of Wiskott-Aldrich syndrome-related disorder, who was successfully treated with dupilumab.
Topics & Concepts
DupilumabMedicineAtopic dermatitisContext (archaeology)Primary immunodeficiencyDermatologyWiskott–Aldrich syndromeEczematous dermatitisImmunologyImmune systemBiologyPaleontologyChemistryBiochemistryGeneDermatology and Skin DiseasesAsthma and respiratory diseasesAllergic Rhinitis and Sensitization